INtRON Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 02:06 am
Share
iNtRON Biotechnology, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 0.35353 million compared to KRW 0.34118 million a year ago. Net loss was KRW 1,683.58 million compared to net income of KRW 2,294.65 million a year ago. Basic loss per share from continuing operations was KRW 50 compared to basic earnings per share from continuing operations of KRW 60 a year ago. Diluted loss per share from continuing operations was KRW 50 compared to diluted earnings per share from continuing operations of KRW 60 a year ago. Basic loss per share was KRW 50 compared to basic earnings per share of KRW 60 a year ago. Diluted earnings per share was KRW 15.
For the nine months, sales was KRW 1.37 million compared to KRW 1.07 million a year ago. Net income was KRW 9,279.29 million compared to KRW 7,177.09 million a year ago. Basic earnings per share from continuing operations was KRW 273 compared to KRW 329 a year ago. Diluted earnings per share from continuing operations was KRW 65 compared to KRW 329 a year ago. Basic earnings per share was KRW 273 compared to KRW 329 a year ago. Diluted earnings per share was KRW 65.
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
INTRON BIOTECHNOLOGY, INC. 
